What question did this study set out to answer?

To determine whether the common lipoprotein lipase truncation variant (Ser447X) alters plasma lipid levels and reduces coronary heart disease risk in the general population.

June 1, 1999Clinical Genetics

A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study

View Full Paper

Ask AI

Bookmark

Why the study?

Does the Ser447X variant of the LPL locus reduce the risk of CHD and improve lipid profiles in the general population?

Population

2,258 subjects (1,114 men and 1,144 women) randomly ascertained from the Framingham Offspring Study (FOS)

Comparison

Carrier status of the Ser447X variant at the… vs Non-carriers of the Ser447X variant

Design

Cohort

Authors

SGSe GagnéUniversity of British Columbia MLMartin G. LarsonSemmelweis University SPSn PimstoneUniversity of British Columbia

Discussion

Member takes

Implication

Supports S447X-CHD protection in men; leaves open causal validation and clinical utility in prospective studies.

Key Points

To determine whether the common lipoprotein lipase truncation variant (Ser447X) alters plasma lipid levels and reduces coronary heart disease risk in the general population.
Genotyped 1,114 men and 1,144 women randomly ascertained from the Framingham Offspring Study for the Ser447X variant.
Measured associations between Ser447X carrier status, plasma lipid profiles (total cholesterol, HDL-C, and triglycerides), and coronary heart disease incidence.
The carrier frequency of the Ser447X allele was 17% in the overall population.
In men, carrier status was significantly associated with higher total cholesterol (delta = 6.2 mg/dl, p = 0.03), higher HDL-C (delta = 2.3 mg/dl, p = 0.01), and lower triglycerides (delta = -19.4 mg/dl, p = 0.02).
Male carriers experienced significant protection against coronary heart disease (odds ratio: 0.43, p = 0.04), whereas no significant associations with lipids or disease risk occurred in women.

Structured PICO

Does the Ser447X variant of the LPL locus reduce the risk of CHD and improve lipid profiles in the general population?

Population

2,258 subjects (1,114 men and 1,144 women) randomly ascertained from the Framingham Offspring Study (FOS)

Intervention

Carrier status of the Ser447X variant at the lipoprotein lipase (LPL) locus

Comparator

Non-carriers of the Ser447X variant

Outcome

Coronary heart disease (CHD) and plasma lipid levels (total cholesterol, HDL-C, triglycerides)hard clinical

The Ser447X variant of the LPL locus is associated with a more favorable lipid profile and a significantly reduced risk of coronary heart disease in men.

Cite This Study

Gagné et al. (1999) studied this question.

synapsesocial.com/papers/6a7deecd7c193befc433a576 https://doi.org/10.1034/j.1399-0004.1999.550609.x

View Full Paper

Ask AI

Bookmark

A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

A common truncation variant of lipoprotein lipase (Ser447X) confers protection against coronary heart disease: the Framingham Offspring Study

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider